Search bioRxiv⌕ Search

Biology subjects

Becker, J. L.

Publications and source records attributed to Becker, J. L..

2 recordsLinked to original sources

Sex, not estrous cycle stage, drives differences in the microglial transcriptome in the 5xFAD mouse model of amyloidosis

Alzheimers disease (AD) presents with a sex bias where women are at higher risk and exhibit worse cognitive decline and brain atrophy compared to men. Microglia play a significant role in the pathogenesis and progression of AD and have been shown to be sexually differentiated in health and disease. Whether microglia contribute to the sex differences in AD remains to be elucidated. Herein, we characterize the sex differences in amyloid-beta (A{beta}) plaque pathology and microglia-plaque interaction using the 5xFAD mouse model of amyloidosis and further elucidate the microglial transcriptomic changes that occur in males and females. In females we concentrate on two hormonally distinct stages of the rodent estrous cycle: proestrus and diestrus. Our results indicate that A{beta} plaque morphology is sexually distinct with females having greater plaque volume and lower plaque sphericity compared to males. Microglia also interact with plaques in a sexually distinct manner with females phagocytosing A{beta} to a greater extent compared to males. Furthermore, we found that female microglia are not overtly different at the proestrus or diestrus stages. However, we found stark sex differences between female and male microglia transcriptomes in the 5xFAD brains, where female 5xFAD microglia were enriched in genes involved in glycolytic metabolism, antigen presentation, disease-associated microglia and microglia neurodegenerative phenotype (DAM/MGnD), and interferon signaling compared to male 5xFAD microglia.

neuroscience↗

Enterococcus peptidoglycan remodeling promotes immune checkpoint inhibitor therapy

The antitumor efficacy of cancer immunotherapy has been correlated with specific species within the gut microbiota. However, molecular mechanisms by which these microbes affect host response to immunotherapy remain elusive. Here we show that specific members of the bacterial genus Enterococcus can promote anti-PD-L1 immunotherapy in mouse tumor models. The active enterococci express and secrete orthologs of the NlpC/p60 peptidoglycan hydrolase SagA that generate immune-active muropeptides. Expression of SagA in non-protective E. faecalis was sufficient to promote antitumor activity of clinically approved checkpoint targets, and its activity required the peptidoglycan sensor Nod2. Notably, SagA-engineered probiotics or synthetic muropeptides also promoted checkpoint inhibitor antitumor activity. Our data suggest that microbiota species with unique peptidoglycan remodeling activity may enhance immunotherapy and could be leveraged for next-generation adjuvants. One Sentence SummaryA conserved family of secreted NlpC/p60 peptidoglycan hydrolases from Enterococcus promote antitumor activity of immune checkpoint inhibitors.

cancer biology↗